Loading

Latest COVID-19 Research Funding Opportunities

The Research Office is open for business and supporting all ongoing activity and new research proposals. Please contact your College's relevant RSO for detail on any of the calls below. Two calls are currently open nationally, coordinated in turn by HRB/ IRC and SFI/EI/IDA and the Research office National Team is supporting submissions to these calls.

Joint Funders' Statement on Covid 19 http://research.ie/2020/03/13/funders-joint-statement-on-covid-19/

Additional Guidance for IRC-funded Researchers http://research.ie/assets/uploads/2020/04/Guidance-for-awardees-on-COVID-19-23.4.2020.pdf

Revised Schedule for IRC Calls 2020 http://research.ie/assets/uploads/2020/04/Revised-Call-Schedule-2020-23-04-2020.pdf

Additional Guidance for HRB-funded Researchers https://www.hrb.ie/funding/manage-a-grant/covid-19-impact-on-active-hrb-grants/

Revised Schedule for HRB Calls 2020 https://www.hrb.ie/news/covid-19-coronavirus/coronavirus-news/article/covid-19-and-funding-scheme-date-changes/

The first focus area targets medical countermeasures, health service readiness, and social and policy countermeasures to COVID-19. The second focus area is an agile and adaptive initiative to combine the capabilities of industry and academia in the development of innovative solutions that can have a rapid demonstrable impact on the current COVID-19 crisis in Ireland. Updated 28th May 2020: Following the launch of the COVID-19 Rapid Response Research and Innovation Funding Programme on March 26th, there have been approximately 350 submissions to date. Please note that owing to the high volume of applications received, announcement of future opportunities has been deferred to June timeframe. Details of the SFI call can be found here.

SFI’s guidance on the Post Award Management of its Grants during the COVID-19 crisis.

There are a number of International schemes open which are being supported by the International Team

Horizon 2020 SC1 - launching a second Covid-19 call on Health. https://ec.europa.eu/research/index.cfm?pg=events&eventcode=BCCAC8CD-C425-DC04-60CB217E492CC7BA

PRACE support to mitigate impact of COVID-19 pandemic https://prace-ri.eu/prace-support-to-mitigate-impact-of-covid-19-pandemic/

For all Wellcome Trust provisional applicants and current grant holders, please refer to the link: https://wellcome.ac.uk/grant-funding/guidance/coronavirus-covid-19-information-grant-applicants-and-grantholders

Other Open Calls:

Research Collaborative in Quality and Patient Safety COVID-19, (Call Opening on 26-06-20, Subject to Board Approval)

The RCQPS Awards support high quality research projects where knowledge users and academic researchers collaborate to focus on QPS research questions that are determined by the documented needs of the Irish health care system. The Research Collaborative in Quality and Patient Safety (RCQPS) is a collaborative initiative between the Health Research Board, the Health Service Executive, National Quality Improvement Team and the Royal College of Physicians of Ireland.

As a result of the COVID-19 global pandemic, RCQPS is now launching a funding opportunity to support the national research response to the virus outbreak. The COVID-19 crisis has meant health and social care systems have had to rapidly adapt and put new processes and procedures in place for patients and all health care related workers. There is a unique opportunity to learn from these adaptations and to improve the quality of approaches throughout and beyond this pandemic. The model used for this scheme involves collaboration between knowledge users and academic researchers. The applicant team should designate a Lead Applicant from the research team and the knowledge user team. Those interested in partaking in QPS research are encouraged to register onto the RCQPS Database. The database will be circulated to support and enhance collaboration on research proposals. Funding of up to €140K is available for a project duration of between 3-12 months.. Proposals should be sent electronically to RCQPS at rcqps@rcpi.ie no later than 1pm, 17th July.

RO & RAO Deadline: 10th July 2020

RCQPS Deadline: 17th July 2020, 13:00

Link: https://www.rcpi.ie/research/research-collaborative-in-quality-and-patient-safety/

COVID-19 CALL FOR PROJECT APPLICATIONS ANNOUNCEMENT

Deadline: This is an ongoing call between the opening and closing date, meaning that applicants can submit an application at any time during the period 20th May 2020 – 30th September 2020.

Scope: The projects should look at ways in which cooperation can effectively help address the multiple challenges posed by this COVID-19 crisis across the NPA programme area. Six themes have been identified, where joint collaborative efforts could be beneficial:

A. Clinical aspects: Comparing the different response measures taken by the respective countries, map the rate of infections and observe differences in comparison to national and local COVID strategies; e.g. in rural vs urban areas

B. Health and well being: The impact of self-isolation on people and their mental health – elderly people and other vulnerable groups who already suffer isolation will be impacted even worse from this situation, but there is a wider effect on the entire population which shall be investigated

C. Technology solutions: What e-health solutions already exist and what should be put in place? How can technology be brought to those people who need it and/or don’t know how to use it? What are the technologies with the lowest threshold? How can we fast track innovation?

D. Citizen engagement/ Community response: Small peripheral communities are more self-sufficient, what lessons can they share?

E. Economic impacts: What will be the impact on the public health system now and next year? In what ways have our societies and economies been transformed already? And how will they be transformed in the medium and long term?

F. Emerging themes: project ideas that fit in the rationale of the call, but do not fall within the themes outlined at the time this Call has been opened. Considering that the situation is constantly developing and that new relevant themes might appear at a later point in time, the Programme will consider applications falling under this category, that reflect a change in the situation or an aspect which has been disregarded.

An Umbrella project will be funded to ensure overall coordination of the thematic projects.

Projects are expected to make an overview of and analyse the state of the COVID-19 crisis, as well as successful and less successful practices in the NPA area relevant to the chosen theme and the geographical context, to be able to make recommendations for future actions, policy responses, etc.

Types of projects funded: Please see link below:

Link: http://www.interreg-npa.eu/for-applicants/covid-19-call/

QUEENS UNIVERSITY BELFAST - Covid-19 Funding

The DfE in Queen's University has secured funding to support NI engagement in the next SFI COVID-19 Rapid Response Call. Queen's University would be very keen to work with NUI Galway, our colleagues and researchers to develop collaborations when the new call opens. Please contact the RO National Team for further information.

Link: http://www.qub.ac.uk/coronavirus/research/related-research-activity/funding-calls/

COVID-19 Rapid Response-Now Open

Funder: Science Foundation Ireland, Enterprise Ireland, IDA Ireland

SFI are pleased to announce the reopening of the COVID-19 Rapid Response Call. The second phase of this call will fund projects up to 14 months in duration that build scientific knowledge and develop novel solutions that have the potential to impact society and the economy in the short/medium term.

Applications will be accepted in the following thematic areas:

• - Infection Prevention & Control

• - Understanding the Virus & Host Response

• - STEM-led Solutions for Stimulating & Sustaining Rapid Economic Recovery

To support all-Ireland collaborative research initiatives, SFI has entered into partnership with the Department of the Economy (Northern Ireland), facilitating researchers in Northern Ireland to apply for funding as part of joint proposals.

Deadline: The deadline for submission of applications to this call is 26 August 2020.

For more information on this opportunity visit www.sfi.ie

Link: https://www.sfi.ie/funding/funding-calls/covid19-rapid-response/

Capacity development for disease outbreak and epidemic response in sub-Saharan Africa, in collaboration with Africa CDC

Funding Type: Funding call

Status: OPEN

Deadline: 30/07/2020

Funder: European & Developing Countries Clinical Trials Partnership

Budget: €5M

Scope: The purpose of this Call for Proposals is to establish an African cohort of epidemiologists by supporting institutions in sub-Saharan Africa and Europe that provide master’s training in epidemiology and biostatistics, as part of the Africa CDC’s framework for public health workforce development. Master’s courses with practical field research experience is the preferable level of training as it is relatively short and likely to deliver the required numbers and high-quality fit-for-purpose calibre of personnel that are urgently needed in epidemic zones of sub-Saharan Africa.

Proposals can be submitted by a single institution or consortium of institutions which must provide master’s training in epidemiology for 10 to 15 excellent, early- to mid-career researchers (“EPI Fellows”) based in sub-Saharan Africa and working in a relevant field. The EPI fellows must commit to remain in Africa for a minimum of two years after completing their studies and provide evidence to demonstrate this through a letter of support from their host institution.

Proposals should include institutions with a proven track record in the provision of high-quality master’s training with clear local and regional collaborations with NPHIs (or similar agencies), Ministries of Health and other academic institutions. Proposals must demonstrate the following:

  • A high-quality master’s programme in epidemiology and biostatistics relevant to infectious diseases of importance in sub-Saharan Africa.
  • An open, fair and transparent procedure for selecting EPI Fellows based in different geographical regions of Africa, and with appropriate gender balance, for entry into the master’s programme.
  • Robust mentorship and supervision mechanisms to support EPI Fellows through to timely successful course completion.
  • The master’s programme must include a research component, which must be conducted in a country in sub-Saharan Africa, in collaboration with local or regional NPHIs (and/or affiliated agencies) or Ministries of Health.

Proposals should also include support for meetings and conferences for the trainees to participate in an annual networking meeting organised by Africa CDC, as well as the biennial EDCTP Forum. Tuition fees, enrolment fees or other types of university charges are not eligible for reimbursement by EDCTP.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://www.edctp.org/call/capacity-development-for-disease-outbreak-and-epidemic-response-in-sub-saharan-africa-in-collaboration-with-africa-cdc/

Date added / Updated 2020-04-21

Swiss National Research Programme on COVID 19

Funding Type: Funding call

Deadline: TBC

Funder: Swiss National Science Foundation

Budget: CHF20M

Scope: The call is divided into four modules:

  • Basic aspects of SARS-CoV-2 biology, pathogenicity and immunogenicity
  • New approaches in COVID-19 epidemiology and disease prevention
  • COVID-19 vaccine, drug development and diagnostics
  • Clinical COVID-19 research and therapeutic interventions

The duration of the project is maximum 24 months. The total amount for the Progamme is CHF 20 mio. (ca. € 19 mio). The project size can vary between CHF 300’000 and CHF 2 mio.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://www.admin.ch/gov/de/start/dokumentation/medienmitteilungen.msg-id-78806.html

Date added / Updated 2020-04-27

UKRI Open call for research and innovation ideas to address COVID-19

Funding Type: Funding call

Status: OPEN

Deadline: Rolling

Funder: UK Research and Innovation (UKRI)

Budget: N/A

Scope: Proposals are invited for short-term projects addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak. UKRI will support excellent proposals up to 12-18 months duration which meet at least one of the following:

  • new research or innovation with a clear impact pathway that has the potential (within the period of the grant) to deliver a significant contribution to the understanding of, and response to, the COVID-19 pandemic and its impacts.
  • supports the manufacture and/or wide scale adoption of an intervention with significant potential
  • gathers critical data and resources quickly for future research use

Irish HEIs Eligible: Yes. Ireland-based researchers are eligible as international co-investigators but the leader of the project must be somebody normally eligible for UKRI funding. More information about UKRI eligibility criteria can be found here

Irish Companies Eligible: No

Link: https://www.ukri.org/funding/funding-opportunities/ukri-open-call-for-research-and-innovation-ideas-to-address-covid-19/

Date added / Updated 2020-04-07

Irish Global Health Network (IGHN) - tracking training courses for Healthcare Professionals

Funding Type: Training

Status: OPEN

Funder: Irish Aid

Budget: N/A

Scope: This page provides an up-to-date listings on training courses relevant to the global health community. The most recent courses are updated from top to bottom on the page.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://globalhealth.ie/training-courses-for-health-professionals/

Diamond Light Source Rapid Access Call for Proposals: SARS-CoV-2

Funding Type: Support

Status: OPEN

Deadline: Rolling

Funder: Diamond Light Source

Budget: N/A

Scope: Rapid access to instruments: Priority rapid access for groups who require instrument time for projects directly related to SARS-CoV-2 viral proteins

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://www.diamond.ac.uk/Users.html

Date added / Updated: 2020-04-06

National Hydrogen Centre Rapid Access to Laboratories and Services

Funding Type: Support

Status: OPEN

Deadline: Rolling

Funder: National Hydrogen Centre, CNH2

Budget: N/A

Scope: Rapid access to our laboratories. In addition, we offer our services, such as, laser cutting machines, 3d printers and machining centres

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://erf-aisbl.eu/wp-content/uploads/RIs-and-COVID19-research-Questionnaire_CNH2.pdf

Date added / Updated: 2020-05-06

AI-Robotics vs COVID-19

Funding Type: Call to Action

Status: OPEN

Deadline: N/A

Funder: European Commission

Budget: NA

Scope: The European Commission launches an initiative to collect ideas about deployable Artificial Intelligence (AI) and Robotics solutions as well as information on other initiatives that could help face the ongoing COVID-19 crisis.

The initiative aims to create a unique repository that is easily accessible to all citizens, stakeholders and policymakers and become part of the common European response to the outbreak of COVID-19.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://ec.europa.eu/digital-single-market/en/news/join-ai-robotics-vs-covid-19-initiative-european-ai-alliance

Date added / Updated: 2020-03-31

EOSC - Fast track Process for Covid-19 Co-creation Request

Funding Type: Funding Call

Status: OPEN

Deadline: Applications will be evaluated on a weekly basis.

Funder: European Open Science Cloud

Budget: €45,000 max

Scope: Activities and actions that deploy open science methods and resources and make use of the EOSC communities in order to address COVID-19 related issues. Indicatively, these could be:

• Opening up virus related research and data

• Sharing of infrastructures and services

• Developing open design equipment for fighting COVID-19

• Sharing sampling test methodologies and data

• Developing open methodologies, services, software and infrastructures for sharing data, practices and knowledge in relation to the development and treatment of COVID-19

• Developing open science methodologies for monitoring the spread of COVID-19

• Developing open-science / evidence-based methodologies for the development of epidemic combating policies

• Accessing and combining open data not only to eradicate the virus but learn how to deal with similar viruses and future outbreaks

• Assessing the validity of epidemic information in relation to the virus by ensuring that its sources can be traced and verified

• Other open science activities/ actions related to the fighting of epidemics and pandemics

Irish HEIs Eligible: Yes. Eligibility according to H2020 criteria

Irish Companies Eligible: Yes. Eligibility according to H2020 criteria

Link: https://www.eoscsecretariat.eu/sites/default/files/eoscsecretariat_-_fast_track_process_for_covid-19_co-creation_requests.pdf

Date added / Updated: 2020-03-31

ELECMI – Rapid access to instruments

Funding Type: Support

Status: OPEN

Deadline: Rolling

Funder: ELECMI (Integrated Infrastructure of ELECtron MIcroscopy for materials Characterization)

Budget: N/A

Scope: Rapid access to instruments: Researchers can perform studies on materials characterisation, such as the analysis of textiles for Personal Protective Equipment or particles from filters

Irish HEIs Eligible: Yes

Irish Companies Eligible: No

Link: https://erf-aisbl.eu/wp-content/uploads/RIs-and-COVID19-research-Questionnaire_ELECMI.pdf

Date added / Updated: 2020-05-06

Elettra Synchrotron – Rapid access to instruments

Funding Type: Support

Status: OPEN

Deadline: Rolling

Funder: Elettra - Sincrotrone Trieste

Budget: N/A

Scope: Elettra - Sincrotrone Trieste aims to actively contribute to COVID-19 research, giving special priority to experiments related to SARS-CoV-2 viral proteins and studies of possible drugs for viral infection treatment. Researchers from all over the world have the possibility to benefit from remote access to Elettra/FERMI beamlines and perform experiments on a priority basis on the topic.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: http://www.elettra.trieste.it/userarea/covid-19-virus-elettra-rapid-access-proposals.html

Date added / Updated: 2020-04-06

European Spallation Source DEMAX – Prioritised access

Funding Type: Support

Status: OPEN

Deadline: Rolling. ESS will review this position at the end of 2020

Funder: European Spallation Source (ESS)

Budget: N/A

Scope: The Deuteration & Macromolecular Crystallisation (DEMAX) platform at ESS is offering prioritised access to laboratory services for scientists and researchers working on COVID-19-related research projects. It is able to provide expertise, advice and limited materials to support research aimed at the critical need to gain a better understanding of COVID-19

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://europeanspallationsource.se/article/2020/03/27/ess-demax-lab-prioritise-proposals-covid-19-related-research

Date added / Updated: 2020-04-06

Felix Laboratory – Rapid access

Funding Type: Support

Status: OPEN

Deadline: Rolling

Funder: FELIX Laboratory

Budget: N/A

Scope: To support the investigation of the SARS-CoV-2 virus characteristics and the development of possible diagnostics, vaccine and treatments, the FELIX Laboratory offers rapid access to all its endstations for research related to SARS-CoV-2. Although the FELIX free electron lasers are not operating at present we have the option to start operation on short notice if required.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://www.ru.nl/felix/vm/rapid-access-corona-related-research-felix/

Date added / Updated: 2020-04-06

BESSY II Fast Track Access for SARS-CoV-2 proposal

Funding Type: Support

Status: OPEN

Deadline: Rolling

Funder: Helmholtz-Zentrum Berlin für Materialien und Energie (HZB)

Budget: N/A

Scope: BESSY II at HZB is not in user operation at present, however for corona-related research during the stand-by operation, the three MX-beamlines of HZB will be open to receiving external projects. BESSY II provides tools and expertise to advance the work on SARS-CoV-2 and identify potential weaknesses of the virus. All data and results are immediately available to the entire scientific community so that active substances can be developed as quickly as possible.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://www.helmholtz-berlin.de/user/index_en.html

Date added / Updated: 2020-04-06

ILL Response to the Challenges Posed by Covid-19

Funding Type: Support

Status: OPEN

Deadline: Rolling

Funder: Institut Laue-Langevin (ILL)

Budget: N/A

Scope: At the ILL, we plan to run 2 more cycles in 2020 which will constitute a significant opportunity to perform early research related to Covid-19 on many of our neutron scattering.

ILL scientists working in the field of biology are fully committed to applying their expertise to the fight against Covid-19, building on their previous insightful discoveries instruments. In addition to the instruments, we have deuteration facilities and share biology and soft matter facilities with our partner institutes on the the EPN campus - the ESRF, EMBL and IBS.

We also expect the research community to work on Covid-19 on a longer timescale. We encourage you to think about the role of neutrons and discuss longer-term projects with scientists at ILL. These projects may require PhD students which the ILL can support through its PhD programme (next call autumn 2020) and the InnovaXN programme, running with the ESRF, for which the second call for projects involving industry partners will be opened shortly, with a view to selecting 20 more projects by July 2020.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://www.ill.eu/news-press-events/news/general-news/coronavirus-covid-19/

Date added / Updated: 2020-04-06

Instruct-ERIC: Priority access for research proposals relating to COVID-19 virus

Funding Type: Support

Status: OPEN

Deadline: Rolling

Funder: Instruct-ERIC

Budget: N/A

Scope: Where possible, Instruct-ERIC will continue to offer restricted access to structural biology services for researchdirectly related to COVID-19, through a priority access pathway. Priority access ensures a faster review of research proposals relating to COVID-19. A full list of the Instruct services that are available during the restricted period, including remote access, is available at https://instruct-eric.eu/news/resources-information-and-collaborations-to-support-covid19-research/

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://instruct-eric.eu/news/priority-access-for-research-proposals-relating-to-covid-19-virus/

Date added / Updated: 2020-04-06

Fast Funding for COVID-19 Science

***Applications are paused. Due to receipt of a very large number of qualified submissions, Fast Grant applications are currently closed. We may reopen them in the future.***

Science funding mechanisms are too slow in normal times and may be much too slow during the COVID-19 pandemic. Fast Grants are an effort to correct this.

If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. If we approve the grant, you'll receive payment as quickly as your university can receive it.

Who is eligible to apply for a Fast Grant?

You must be:

• A PI at an academic institution;

• Already working on a project that could help with the COVID-19 pandemic within the next six months;

• In need of additional funding to complete the project.

Applications can be submitted through the following link.

Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) RFA-AI-20-028

Funding Type: Funding call

Deadline: 29th June 2020. Letters of intent (not essential) can be submitted to: Maryam Feili-Hariri, PhD National Institutes of Allergy and Infectious Diseases (NIAID). Telephone: 240-669-5026 Email: haririmf@niaid.nih.gov

Funder: Department of Health and Human Services via the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID), US

Budget: NIAID intends to commit $10.5 million in FY2021 to fund 10-15 awards.

Scope: The purpose of this Funding Opportunity Announcement(FOA) is to solicit research applications for milestone-drivenprojects focused on preclinical development of lead candidatetherapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-028.html#_Section_II._Award_1

The ICHEC is offering fast-track access to its Kay supercomputer to those conducting coronavirus-related research.

Funding Type: Support

Status: OPEN

Deadline: N/A

Funder: Irish Centre for High-End Computing (ICHEC)

Budget: The ICHEC said it will provide up to 1m core hours and 1TB of storage for each approved project.

Scope The ICHEC is offering fast-track access to its Kay supercomputer to those conducting coronavirus-related research.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://www.siliconrepublic.com/machines/ichec-kay-supercomputer-coronavirushttps://www.ichec.ie/about

BARDA BAA-18-100-SOL-00003, AOI #9.5: Pre-exposure and Post-exposure Prophylaxis

Funding Type: Funding Call

Status: OPEN

Deadline: Deadline 2: 31/07/2020, Deadline Final: 31/10/2020

Funder: Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: N/A

Scope: There is a need to develop antivirals that may be used for pre-exposure prophylaxis for those at high risk of SARS-CoV-2 (2019-nCoV) exposure such as healthcare workers. In BARDA BAA-18-100-SOL-00003 Amendment 14 Page 38 addition, there is a need for post-exposure prophylaxis in those that are at high risk for serious disease caused by SARS-CoV-2 (2019-nCoV). Single dose antivirals that can potentially protect against infection for at least 30 days will be prioritized for consideration. BARDA will prioritize platform candidates with demonstrated safety in a phase 1 study; however, earlier stage candidates may be considered. Immune modulating mechanisms of action or candidates that require daily dosing will be considered non-responsive. Manufacturing of products in the United States will be a requirement.

Note: Development programs at a maturity level less than TRL6 should consider funding opportunities offered by The National Institute of Allergy and Infectious Diseases (NIAID) or other Federal agencies that fund earlier stage R&D projects.

Irish HEIs Eligible: Yes.

Manufacturing of products in the United States will be a requirement.

These Special Instructions 003 are open to all responsible sources as described in the EZ-BAA.

Preliminarily, a call with the relevant Program Manager is strongly encouraged prior to any submission to better understand and confirm the program objectives and eligibility:

Technical inquiries about funding through NIAID programs can be directed to: DMIDResources@niaid.nih.gov Technical Point of Contact: Dr. Kimberly Armstrong; Kimberly.Armstrong@hhs.gov Contracting Point of Contact: Wendell Conyers; Wendell.Conyers@hhs.gov

Irish Companies Eligible Yes

Manufacturing of products in the United States will be a requirement.

These Special Instructions 003 are open to all responsible sources as described in the EZ-BAA.

Preliminarily, a call with the relevant Program Manager is strongly encouraged prior to any submission to better understand and confirm the program objectives and eligibility:

Technical inquiries about funding through NIAID programs can be directed to: DMIDResources@niaid.nih.gov

Technical Point of Contact: Dr. Kimberly Armstrong; Kimberly.Armstrong@hhs.gov

Contracting Point of Contact: Wendell Conyers; Wendell.Conyers@hhs.gov

Link: https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

Date added / Updated: 2020-03-24

BARDA BAA-18-100-SOL-00003, AOI #10.1: Development and characterization of improved respiratory protective devices (RPD).

Funding Type: Funding Call

Status: OPEN

Deadline: Deadline 2: 31/07/2020, Deadline Final: 31/10/2020

Funder: Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: N/A

Scope: Support for advanced development of improved RPDs such as masks, surgical masks, PAPRs, elastomeric masks, elastomeric half mask, or respirators to reduce transmission of influenza virus and other infectious agents. These RPDs should demonstrate improved features over currently available products. Examples of desirable improvements: • reduced cost of at least an order of magnitude to acquire and stockpile, • manufacturing efficiency or speed, • decontamination and re-use, • functionality, • fit flexibility to support a broad population (e.g., pediatric through adult), • elimination of fit testing, • usability, comfort. All proposed products must have a clear path to NIOSH certification and FDA clearance as applicable. Proposed activities should offer beneficial clinical and public health impact with a TRL 4 or greater.

Irish HEIs Eligible: Yes

These Special Instructions 003 are open to all responsible sources as described in the EZ-BAA.

Preliminarily, a call with the relevant Program Manager is strongly encouraged prior to any submission to better understand and confirm the program objectives and eligibility: Technical Point of Contact: Rodney Wallace; Rodney.Wallace@hhs.gov. Contracting Point of Contact: Wendell Conyers; Wendell.Conyers@hhs.gov

Irish Companies Eligible: Yes

These Special Instructions 003 are open to all responsible sources as described in the EZ-BAA.

Preliminarily, a call with the relevant Program Manager is strongly encouraged prior to any submission to better understand and confirm the program objectives and eligibility:

Technical Point of Contact: Rodney Wallace; Rodney.Wallace@hhs.gov

Contracting Point of Contact: Wendell Conyers; Wendell.Conyers@hhs.gov

Link: https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

Date added / Updated 2020-03-24

BARDA BAA-18-100-SOL-00003, AOI #11: Ventilators

Funding Type: Funding Call

Status: OPEN

Deadline: 31/07/2020, 31/10/2020 04:30 pm EDT

Funder: Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: Not Available

Scope: Advanced development of new or improved ventilators to provide respiratory support in clinical care, transport, and emergency use settings for severe respiratory conditions resulting from influenza infections or All-Hazards incidents.

Ideal ventilators should:

• be portable;

• support neonate (≥ 2.5kg) to adult populations;

• be easy to set up, select initial ventilation settings, and troubleshoot by minimally trained care providers;

• be able to use other manufacturers’ breathing circuits;

• be low maintenance for ease of stockpiling;

• accommodate/provide accessories typically used in ventilator standard of care;

• consider low resource environments (where power and oxygen may be limited);

• and have a low cost per unit

Offeror should also be able to accommodate domestic surge production capacity. TRL 4 or greater

Irish HEIs Eligible: Yes

This BAA is open to ALL responsible sources. Offerors may include single entities or teams from private sector organizations, Government laboratories, and academic institutions.

Technical Point of Contact: Rodney Wallace; Rodney.Wallace@hhs.gov

Contracting Point of Contact: Wendell Conyers; Wendell.Conyers@hhs.gov

Irish Companies Eligible: Yes

Link: https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

BARDA BAA-18-100-SOL-00003, AOI #17: Advanced Manufacturing Technologies

Funding Type: Funding Call

Status: OPEN

Deadline: 31/07/2020, 31/10/2020 04:30 pm EDT

Funder: Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: Not Available

Scope: The development and demonstration of innovations and enhancements to manufacturing platforms to support the development of necessary medical countermeasures including vaccines and therapeutics in prevention, preparation, and response to COVID-19. The purpose of the innovations and enhancement to advanced manufacturing technologies may include but is not limited to improving pharmaceutical quality, rapidly scale manufacturing capabilities, shorten supply chains, increase manufacturing resilience to disruption, accelerate availability of emerging therapies/vaccines, and reduce the risk of pharmaceutical shortages. Advanced manufacturing technologies may include but is not limited to continuous manufacturing and additive manufacturing (including 3D printing).

Submission of Quad Chart, White Paper, and a Rough Order of Magnitude (ROM) estimate of costs, not a full proposal.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Priority will be given to products manufactured in the United States.

Technical Point of Contact: Timothy Belski; Timothy.Belski@hhs.gov

Contracting Point of Contact: Carol Lavrich; Carol.Lavrich@hhs.gov

Link: https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

BARDA BAA-18-100-SOL-00003, AOI #7.7.1: Diagnostic assay for human coronavirus using existing FDA-cleared platforms

Funding Type: Funding Call

Status: OPEN

Deadline : 31/07/2020 , 31/10/2020

Funder: Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: N/A

Scope: BARDA is seeking proposals for the development, and FDA clearance of an in vitro diagnostic pan-coronavirus assay that can also differentiate known human coronaviruses (SARS-CoV-2 (2019-nCoV), MERS-CoV, CoV 229E, CoV OC43, CoVNL63, and CoV HKU1) in clinical specimens. Differentiation of SARS-CoV is also desired if Offeror has an appropriate regulatory strategy for FDA clearance or pre-EUA.The pan-coronavirus assay should be designed to ensure high probability of detecting any future novel or emerging coronavirus that infects humans. The assay should bedesigned to test clinical specimens including upper (e.g, nasopharyngeal and oropharyngeal swabs, nasopharyngeal wash/aspirate or nasal aspirate) and lower (e.g.,bronchoalveolar lavage, tracheal aspirate, sputum) respiratory tract specimens and blood (whole blood, plasma or serum). BARDA prefers assays that will be used with anexisting FDA-cleared molecular platform that is currently widely placed in U.S. healthcare settings. Minimum Technology Readiness level (TRL) for this assay is TRL4, in silico evaluation for all proposed targets is required. BARDA will also prioritize manufacturing in the United States.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Preliminary, a call with the relevant Program Manager is strongly encouraged prior to any submission to better understand the program objectives and eligibility: Rodney.Wallace@hhs.gov

Link https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

BARDA BAA-18-100-SOL-00003, AOI #7.7.2: Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus

Funding Type: Funding Call

Status: OPEN

Deadline: 31/07/2020, 31/10/2020

Funder Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: N/A

Scope: BARDA is seeking the development, Emergency Use Authorization (EUA), and 510k clearance of an in vitro diagnostic assay for the detection of SARS-CoV-2 (i.e., virus, viral RNA, or viral antigens) in respiratory specimens that has a small foot-print (i.e. hand held), and is easy to use at the point of care (i.e., suitable for use in CLIA-waived settings) and produces results in less than 30 minutes (less than 15 minutes preferred). Minimum Technology Readiness level (TRL) for the platform is TRL-5, and for the assay is TRL-4. Offerors should describe the platform, data to support utility for respiratory samples, proposed assay targets, development status of the SARS-CoV-2 assay and platform, regulatory pathway, and access to validation materials to support EUA submission. BARDA will also prioritize manufacturing in the United States.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Priority will be given to products manufactured in the United States.

Preliminarily, a call with the relevant Program Manager is strongly encouraged prior to any submission to better understand the program objectives and eligibility: Rodney.Wallace@hhs.gov

Link https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

BARDA BAA-18-100-SOL-00003, AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)

Funding Type: Funding call

Status: OPEN

Deadline: 31/07/2020, 31/10/2020 04:30 pm EDT,

Funder: Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: N/A

Scope: BARDA is seeking the development, Emergency Use Authorization (EUA) and 510k clearance of an in vitro diagnostic assay for COVID-19 (i.e., SARS-CoV-2 infection) that has a small foot-print (i.e. hand held), and is easy to use at the point of care (i.e., suitable for use in CLIA-waived settings). Assays should detect host or pathogen biomarkers specific for acute COVID-19 disease in non-invasive specimens that can be easily collected in CLIA-waived settings, and provide results in less than 30 minutes(less than 15 minutes preferred).

BARDA will prioritize platforms and assays for detection of COVID-19 disease that have reached TRL-4 level. Offerors should describe development status of the platform, the proposed COVID-19 specific biomarkers, development status of the assay, access to patient samples, clinical studies, regulatory pathway and report of discussion with FDA regarding EUA data requirements. At a minimum, include proof of concept data on the proposed platform to demonstrate ability to discriminate etiology of other respiratory infections (e.g., can differentiate influenza infection from other respiratory virus infections) is required.

BARDA will also prioritize manufacturing in the United States.For technologies requiring additional data to reach TRL-4, interested parties are encouraged to review the opportunities available in the COVID-19 EZ-BAA21.

Technical Point of Contact: Rodney.Wallace@hhs.gov

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Preliminarily, a call with the relevant Program Manager is stronglyencouraged prior to any submission to better understand the program objectives and eligibility: Rodney.Wallace@hhs.gov

Link https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

BARDA BAA-18-100-SOL-00003, AOI #8.3: COVID-19 Vaccine

Funding Type: Funding Call

Status: OPEN

Deadline: 31/07/2020, 31/10/2020 04:30 pm EDT

Funder: Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: N/A

Scope: A challenge to the national and global health security is the newly emerged SARS-CoV2 virus. BARDA is seeking proposals for the development of vaccine countermeasures to this newly emerged disease. The countermeasure produced may consist of the vaccine itself, viral or genetic (DNA or RNA) vectors, or other technologies that can quickly generate a safe and protective immune response. The manufacturing technology for the proposed vaccine should be suitable for commercial scale production and for product delivery. The description of the manufacturing process should address domestic bulk and fill finish manufacturing timelines, the ramp-up time for additional doses based on the approximate dosage versus existing capacity, and take into account any need for process scale-up or finding new capacity. Manufacturing must occur in the United States. The pre-clinical and clinical testing plan, as well as the regulatory pathway, for obtaining approval for use of the vaccine developed should be outlined. Regulatory challenges should be identified and addressed. The technology readiness level (TRL) of the vaccine should be described. While there is no TRL minimum requirement, more advanced submissions are preferred. Preference will be given to technologies that leverage late stage or licensed platforms and those that have non-clinical data from SARS or MERS-CoV and human exposure data to include safety and potential immunogenicity.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Priority will be given to products manufactured in the United States. These Special Instructions 003 are open to all responsible sources as described in the EZ-BAA.

Respondents must be registered in the System for Award Management (SAM) with the appropriate North American Industry Classification System code prior to proposal submission.

Registration can be completed here: https://sam.gov/SAM/

Preliminarily, a call with the relevant Program Manager is strongly encouraged prior to any submission to better understand the program objectives: Armen Donabedian, armen.donabedian@hhs.gov

Link https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

BARDA BAA-18-100-SOL-00003, AOI #9.2: COVID-19 Therapeutics.

Funding Type: Funding Call

Status: OPEN

Deadline: 31/07/2020, 31/10/2020 04:30 pm EDT

Funder: Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: N/A

Scope: Direct acting antivirals with proven efficacy against coronaviruses. In vitro efficacy versus human coronaviruses is required. The best proposals will demonstrate efficacy in vitro and in vivo versus MERS-CoV, SARS-CoV, or SARS-CoV-2 (2019-nCoV). In addition to the in vitro and in vivo efficacy prioritization, repurposed products that are already FDA approved or in late stages of development with clinical exposure data will be prioritized. Host-directed therapeutics, which indirectly inhibit the coronavirus virus lifecycle will also be considered. Demonstrated efficacy versus human coronaviruses in vitro is required. The best proposals will demonstrate in vitro or in vivo efficacy against SARS-CoV, MERS-CoV, or SARS-CoV-2 (2019-nCoV). In addition to the in vitro and in vivo efficacy prioritization, repurposed products that are already FDA approved or in late stages of development with clinical exposure data will be prioritized. BARDA BAA-18-100-SOL-00003 Amendment 14 Page 37 BARDA will prioritize candidates against SARS-CoV-2 (2019-nCoV) that have reached the TRL6 level, however, earlier stage candidates may be considered. Manufacturing of products in the United States will be a requirement.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Technical inquiries about funding through NIAID programs can be directed to: DMIDResources@niaid.nih.gov

Technical Point of Contact: Dr. Kimberly Armstrong; Kimberly.Armstrong@hhs.gov

Contracting Point of Contact: Wendell Conyers; Wendell.Conyers@hhs.gov

Link https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

BARDA BAA-18-100-SOL-00003, AOI #9.3: Immunomodulators or therapeutics targeting lung repair

Funding Type: Funding Call

Status: OPEN

Deadline: 31/07/2020, 31/10/2020 04:30 pm EDT 

Funder: Biomedical Advanced Research and Development Authority (BARDA) under the U.S. Department of Health and Human Services, US

Budget: N/A

Scope: Immunomodulators that improve the clinical response to and/or resolution of symptoms associated with influenza or other viral respiratory infections will be considered. Product candidates must demonstrate efficacy as measured by a significant reduction in morbidity, mortality, viral titers, or a significant change in immunological markers (for example) in relevant influenza or viral respiratory disease animal models. Proposed candidates must have an active Investigational New Drug application filed with the FDA and have demonstrated safety in a Phase 1 study as evidenced by a final clinical study report. BARDA will prioritize candidates against SARS-CoV-2 (2019-nCoV), related coronaviruses, or respiratory infections that have reached the TRL6 level, however, earlier stage candidates may be considered. Candidates that do not have data for respiratory disease will be considered nonresponsive. Manufacturing of products in the United States will be a requirement.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Manufacturing of products in the United States will be a requirement.

Technical inquiries about funding through NIAID programs can be directed to: DMIDResources@niaid.nih.gov

Technical Point of Contact: Dr. Kimberly Armstrong; Kimberly.Armstrong@hhs.gov

Contracting Point of Contact: Wendell Conyers; Wendell.Conyers@hhs.gov

Link: https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

Irish Global Health Network (IGHN) - tracking training courses for Healthcare Professionals

Funding Type: Training

Status: OPEN

Deadline: N/A

Funder: Irish Aid

Budget N/A

Scope: This page provides an up-to-date listings on training courses relevant to the global health community. The most recent courses are updated from top to bottom on the page.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link https://globalhealth.ie/training-courses-for-health-professionals/

COVID-19: Tackling the Novel Coronavirus - FREE online course

Funding Type: Training

Status: OPEN

Deadline: Started 23/03/2020 but you can join and catch up at any time.

Funder: London School of Hygience & Tropical Medicine (LSHTM)

Budget N/A

Scope Audience: Those working in or around health, or anyone interested in how we should respond to the outbreak.

What you will cover:

• How COVID-19 emerged and was identified

• How COVID-19 spreads

• Public health measures for COVID-19 worldwide

• What is needed to address COVID-19 going forward

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link: https://www.futurelearn.com/courses/covid19-novel-coronavirus

ELIXIR support for SARS-CoV-2 research

Funding Type: Support

Status: OPEN

Deadline: on-going

Funder: ELIXIR is an intergovernmental organisation that brings together life science resources from across Europe, funded by the EU, Member States and International Organisations

Budget N/A

Scope: As the ESFRI Research Infrastructure for life science data, ELIXIR Nodes provide a range of services that can be used by researchers and consortia working on SARS-CoV-2 research.

Irish HEIs Eligible: Yes

Irish Companies Eligible: TBC

The COVID19 services, including the data and tools,are open to industry, encouraging SME participation, with minor restrictions in place in certain circumstances.

Link: https://elixir-europe.org/covid-19-resources

Open Source Ventilator (OSV) Ireland

Funding Type: Call to Action

Status: OPEN

Deadline N/A

Funder

Budget NA

Scope: OSV Ireland was formed by Colin Keogh, Conall Laverty & David Pollard, with the goal of building a focused team in Ireland to begin development of a Field Emergency Ventilator (FEV) in partnership with the Irish Health Service. To date we have formed a team of engineers, designers and medical practitioners to develop new, low resource interventions, all working collaboratively online. Bag Valve Masks (BVM), 3D printed and traditionally manufactured components are being considered to maximise potential manufacturing capabilities. We will also include other challenges and problems as they arise from frontline healthcare workers, which we will encourage our volunteers to tackle.

Register your interest to get involved on the website and if your skills are needed, the team will get in touch.

Irish HEIs Eligible: Yes

Irish Companies Eligible: Yes

Link https://opensourceventilator.ie/

The following links may be useful for any H2020 Grant Queries:

Related to the Covid-19 outbreak, what happens to costs in Horizon 2020 grants when there are difficulties in implementing the action due to the Covid-19 situation?

Related to the Covid-19 outbreak, Horizon 2020 deadline updates, the Commission are reviewing deadlines on an individual call by call basis.

Related to the Covid-19 outbreak, current coordinators and beneficiaries with one of the Horizon 2020 programmes please see the COVID-19 outbreak: new (Horizon 2020) FAQs link published by the European Commission.

Related to the Covid-19 outbreak, is it possible in Horizon 2020 grants to postpone the starting date of the action?

Related to the Covid-19 outbreak, how will the funding bodies handle possible delays in submitting deliverables and reports in Horizon 2020 grants?

Related to the Covid-19 outbreak, what happens in Horizon 2020 grants if beneficiaries cannot submit all/complete elements for their reports related to interim and final payments?

Is there any possibility to extend the project duration of Horizon 2020 grants due to the Covid-19 situation?

What happens to costs in Horizon 2020 grants when there are difficulties in implementing the action due to the Covid-19 situation?

Is there any possibility to rapidly re-direct work in on-going Horizon 2020 projects to help tackling the Covid-19 outbreak?